What’s Next? Five Things To Look Out For In May
Teva And Viatris Follow Sandoz On Q1; Key Cabometyx Trial Set To Begin
This month, Eli Lilly’s Alimta blockbuster will lose patent protection in the US, while Teva – which will also publish its Q1 financial results – will see Bristol Myers Squibb begin its appeal process against a key UK ruling involving the originator’s Eliquis (apixaban) anticoagulant.
